Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1964
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 1
1968 10
1969 2
1970 3
1971 2
1972 3
1973 6
1974 4
1975 3
1976 4
1977 2
1979 5
1980 3
1981 9
1982 1
1983 3
1984 3
1985 9
1986 4
1987 6
1988 4
1989 5
1990 3
1991 9
1992 15
1993 15
1994 11
1995 18
1996 9
1997 13
1998 17
1999 17
2000 17
2001 20
2002 15
2003 24
2004 35
2005 12
2006 21
2007 11
2008 25
2009 20
2010 20
2011 35
2012 38
2013 37
2014 44
2015 41
2016 46
2017 39
2018 48
2019 40
2020 29
2021 30
2022 29
2023 45
2024 34
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

883 results

Results by year

Filters applied: . Clear all
Page 1
Haemophilias A and B.
Bolton-Maggs PH, Pasi KJ. Bolton-Maggs PH, et al. Lancet. 2003 May 24;361(9371):1801-9. doi: 10.1016/S0140-6736(03)13405-8. Lancet. 2003. PMID: 12781551 Review.
Adeno-Associated Virus Gene Therapy for Hemophilia.
Samelson-Jones BJ, George LA. Samelson-Jones BJ, et al. Annu Rev Med. 2023 Jan 27;74:231-247. doi: 10.1146/annurev-med-043021-033013. Epub 2022 Sep 14. Annu Rev Med. 2023. PMID: 36103998 Free PMC article. Review.
For almost three decades, hemophilia A (HA) and hemophilia B (HB) have served as model disorders for the development of gene therapy. This effort is soon to bear fruit with completed pivotal adeno-associated viral (AAV) vector gene addition trials reporting encourag …
For almost three decades, hemophilia A (HA) and hemophilia B (HB) have served as model disorders for the development of gene t …
Gene therapy for hemophilia.
Nathwani AC. Nathwani AC. Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):569-578. doi: 10.1182/hematology.2022000388. Hematology Am Soc Hematol Educ Program. 2022. PMID: 36485127 Free PMC article. Review.
Another approach (etranacogene dezaparvovec, AMT-061) for hemophilia B is also under review by regulators. There are several other gene therapy approaches in earlier stages of development. ...
Another approach (etranacogene dezaparvovec, AMT-061) for hemophilia B is also under review by regulators. There are several o …
Concizumab: First Approval.
Keam SJ. Keam SJ. Drugs. 2023 Jul;83(11):1053-1059. doi: 10.1007/s40265-023-01912-6. Drugs. 2023. PMID: 37341887 Review.
In March 2023, concizumab was approved in Canada for the treatment of adolescent and adult patients (12 years of age or older) with hemophilia B who have FIX inhibitors and require routine prophylaxis to prevent or reduce the frequency of bleeding episodes. This art …
In March 2023, concizumab was approved in Canada for the treatment of adolescent and adult patients (12 years of age or older) with hemop
Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues.
Leebeek FWG, Miesbach W. Leebeek FWG, et al. Blood. 2021 Sep 16;138(11):923-931. doi: 10.1182/blood.2019003777. Blood. 2021. PMID: 34232980 Free article. Review.
After the first encouraging results of intravenously administered adeno-associated virus (AAV)-based liver-directed gene therapy in patients with severe hemophilia B were reported in 2011, many gene therapy studies have been initiated. Most of these studies, using A …
After the first encouraging results of intravenously administered adeno-associated virus (AAV)-based liver-directed gene therapy in patients …
The More Recent History of Hemophilia Treatment.
Franchini M, Mannucci PM. Franchini M, et al. Semin Thromb Hemost. 2022 Nov;48(8):904-910. doi: 10.1055/s-0042-1756188. Epub 2022 Sep 15. Semin Thromb Hemost. 2022. PMID: 36108649 Free article. Review.
Hemophilia gene therapy: first, do no harm.
Valentino LA, Kaczmarek R, Pierce GF, Noone D, O'Mahony B, Page D, Rotellini D, Skinner MW. Valentino LA, et al. J Thromb Haemost. 2023 Sep;21(9):2354-2361. doi: 10.1016/j.jtha.2023.06.016. Epub 2023 Jun 21. J Thromb Haemost. 2023. PMID: 37353081 Free article. Review.
Here, we review data leading to the regulatory authorization of valoctocogene roxaparvovec, an adeno-associated virus 5 gene therapy, in Europe to treat hemophilia A and etranacogene dezaparvovec-drlb in the United States and Europe to treat hemophilia B. We also pr …
Here, we review data leading to the regulatory authorization of valoctocogene roxaparvovec, an adeno-associated virus 5 gene therapy, in Eur …
Fidanacogene Elaparvovec: First Approval.
Dhillon S. Dhillon S. Drugs. 2024 Apr;84(4):479-486. doi: 10.1007/s40265-024-02017-4. Epub 2024 Mar 12. Drugs. 2024. PMID: 38472707 Review.
883 results